Short communicationDeprenyl decreases an endogenous parkinsonism-inducing compound, 1-BENZYL-1,2,3,4-TETRAHYDROISOQUINOLINE (cas 19716-56-4) in mice: in vivo and in vitro studies

Add time:09/08/2019    Source:sciencedirect.com

We examined the effect of deprenyl, a promising drug for the therapy of Parkinson's disease on the formation of a parkinsonism-inducing compound, 1-BENZYL-1,2,3,4-TETRAHYDROISOQUINOLINE (cas 19716-56-4) (1BnTIQ). The 1BnTIQ content was significantly decreased in the brain of deprenyl-treated mouse in vivo, and deprenyl also inhibited 1BnTIQ formation from phenethylamine by a mouse brain homogenate supernatant in vitro. In vivo, the content of a parkinsonism-preventing compound, 1-methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) was slightly increased in mice injected with deprenyl. The marked decrease of the ratio of 1BnTIQ to 1MeTIQ might play a role in the clinical effect of deprenyl.

We also recommend Trading Suppliers and Manufacturers of 1-BENZYL-1,2,3,4-TETRAHYDROISOQUINOLINE (cas 19716-56-4). Pls Click Website Link as below: cas 19716-56-4 suppliers

Prev:Chronic administration of 1-BENZYL-1,2,3,4-TETRAHYDROISOQUINOLINE (cas 19716-56-4), an endogenous amine in the brain, induces parkinsonism in a primate☆
Next:A convenient synthesis of 2-methoxy-1-naphthyl sulfoxides in high enantiomeric purity. A new asymmetric synthesis of 1-BENZYL-1,2,3,4-TETRAHYDROISOQUINOLINE (cas 19716-56-4)s☆)